Filing Analysis
Tempest Therapeutics issued a clinical update at the ISCT 2026 Annual Meeting and updated its corporate presentation for investors.
Key Facts
- Company issued a press release titled 'Tempest Presents Clinical Update at ISCT 2026 Annual Meeting' on May 6, 2026.
- An updated corporate presentation dated May 2026 was posted to the company's website.
- The clinical update was presented at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting.
Tempest Therapeutics announced its financial results for the fiscal year ended December 31, 2025, and provided business highlights. The disclosure was made via a press release furnished to the SEC on March 30, 2026.
Key Facts
- Announced financial results for the fiscal year ended December 31, 2025
- Press release issued and dated March 30, 2026
- Information furnished under Item 2.02 regarding results of operations and financial condition
Tempest Therapeutics entered into a $2.0 million private placement (PIPE) involving common stock, pre-funded warrants, and two series of common warrants with institutional and strategic investors. The deal includes participation from Factor Bioscience Inc. and requires stockholder approval for the full exercise of the issued warrants.
Red Flags
- Small raise size ($2M) relative to typical biotech burn rates may indicate urgent liquidity needs.
- High warrant coverage: The deal includes nearly 2 million warrants for a ~925k share/pre-funded warrant base, which is highly dilutive.
- The requirement for stockholder approval for warrant exercise adds execution risk and potential for future non-compliance.
Key Facts
- The company raised approximately $2.0 million in gross proceeds through the sale of 462,964 shares and 462,963 pre-funded warrants.
- The combined purchase price per share/unit was $2.16.
- The offering includes Series A and Series B warrants for an aggregate of 1,851,854 additional shares of common stock.
- Factor Bioscience Inc. participated as a 'Strategic Investor' in the placement.
- The company must seek stockholder approval for the issuance of shares upon exercise of the Common Warrants within 90 days.
- H.C. Wainwright & Co. acted as the placement agent, receiving fees of 3-6% of gross proceeds.
- Registration rights agreement requires a resale registration statement to be filed within 15 days of the agreement.
Tempest Therapeutics announced interim results from its ongoing REDEEM-1 trial of TPST-2003 and updated its corporate presentation. The company is currently preparing for a potential U.S. registrational study for the candidate in 2026.
Key Facts
- Interim results released for the REDEEM-1 trial evaluating TPST-2003 on February 25, 2026
- Company is preparing for a potential U.S. registrational study in 2026
- Updated corporate presentation dated February 25, 2026, was posted to the company website
- The filing includes Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events)